scholarly journals Valacyclovir for the prevention of CMV disease after renal transplantation: A 5-year follow-up

2002 ◽  
Vol 6 ◽  
pp. S25
Author(s):  
Hans-H. Neumayer ◽  
Jean-Paul Squifflet ◽  
David Lowance ◽  
Christophe M. Legendre
Keyword(s):  
Renal Transplantation ◽  
Cmv Disease

scholarly journals Fertility and Pregnancy in End Stage Kidney Failure Patients and after Renal Transplantation: An Update

2021 ◽  
Vol 2 (2) ◽  
pp. 92-108
Author(s):  
Maurizio Salvadori ◽  
Aris Tsalouchos
Keyword(s):  
Renal Transplantation ◽  
Time Lapse ◽  
Sexual Life ◽  
End Stage Kidney Disease ◽  
Correct Evaluation ◽  
Functional Aspects ◽  
Long Term Follow Up ◽  
End Stage

Sexual life and fertility are compromised in end stage kidney disease both in men and in women. Successful renal transplantation may rapidly recover fertility in the vast majority of patients. Pregnancy modifies anatomical and functional aspects in the kidney and represents a risk of sensitization that may cause acute rejection. Independently from the risks for the graft, pregnancy in kidney transplant may cause preeclampsia, gestational diabetes, preterm delivery, and low birth weight. The nephrologist has a fundamental role in correct counseling, in a correct evaluation of the mother conditions, and in establishing a correct time lapse between transplantation and conception. Additionally, careful attention must be given to the antirejection therapy, avoiding drugs that could be dangerous to the newborn. Due to the possibility of medical complications during pregnancy, a correct follow-up should be exerted. Even if pregnancy in transplant is considered a high risk one, several data and studies document that in the majority of patients, the long-term follow-up and outcomes for the graft may be similar to that of non-pregnant women.

scholarly journals Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 20 ◽  
pp. 168 ◽  
Author(s):  
Wang Xin ◽  
Yang Hui ◽  
Zhang Xiaodong ◽  
Cui Xiangli ◽  
Wang Shihui ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Acute Rejection ◽  
Low Dose ◽  
Opportunistic Infections ◽  
Meta Analysis ◽  
High Dose ◽  
Renal Transplant Recipients ◽  
Significant Difference ◽  
Allograft Loss ◽  
Cmv Disease

Objectives: Valganciclovir 900 mg/day is approved for cytomegalovirus (CMV) prophylaxis, but 450 mg/day is seems also effective. We systematically reviewed the efficacy and safety of low-dose versus high-dose valganciclovir prophylaxis in renal transplantation recipients. Methods: An electronic search was conducted up to November 29, 2016. The primary outcomes were incidences of CMV, CMV disease, mortality and opportunistic infection. The second outcomes were acute rejection, allograft loss, adverse drug reaction (ADR). Results: 7 cohort studies, all with high quality involving (1431 patients) were included. There was no significant difference of the incidence of following CMV disease (1271 patients, odds ratio [OR] 0.74, 95% confidence interval [CI], 0.38-1.43, p=0.36), acute rejection (1343 patients, OR 0.77, 95%CI 0.53-1.14, p=0.19), allograft loss (1271 patients, OR 0.64, 95%CI 0.31-1.35, p=0.24), mortality (1271 patients, OR 0.55, 95%CI 0.20-1.47, p=0.23) and opportunistic infections (OI) (985 patients, OR 0.76, 95%CI 0.52-1.10, p=0.14) between the low-dose and the high-dose valganciclovir  prophylaxis. And no significant difference was observed for premature valganciclovir discontinuation (1010 patients, OR 0.81, 95%CI 0.52-1.25, p=0.33) and the incidence of leukopenia (1082 patients, OR 0.65, 95%CI 0.34-1.22, p=0.18) between the two regimens. Conclusion: 450 mg and 900 mg doses of valganciclovir are equipotent for CMV universal prophylaxis. CMV 450 mg prophylaxis should be used for renal transplant recipients. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

scholarly journals The Evaluation of the Children with Renal Transplant: Single Centre Experience

2020 ◽  
pp. 90-93
Author(s):  
Muhammed Mustafa Özdemir ◽  
Ayşe Seda Pınarbaşı ◽  
Neslihan Günay ◽  
Aynur Gencer-Balaban ◽  
Sibel Yel ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Chronic Kidney Disease Stage ◽  
Clinic Visit ◽  
Disease Stage ◽  
Single Centre Experience ◽  
Ckd Stage ◽  
Underlying Causes ◽  
Stage 1 ◽  
Nephrotic Range Proteinuria

Objective: This study aimed to evaluate patients with renal transplantation in terms of clinical and laboratory parameters. Material and Methods: This study was performed retrospectively with records of 48 patients who underwent renal transplantation before 18 years of age, between June 2008 and July 2019. Results: Congenital malformations of the urinary tract were the most common underlying causes of chronic kidney disease stage 5. Surgical complications occurred in 33.4% of the patients and BK viremia was the most common opportunistic viral infection during the follow-up. At the last clinic visit, 57.4% of our patients had CKD stage 1, hypertension and nephrotic range proteinuria were seen in eight and two patients, respectively. Conclusion: Although renal transplantation is the most ideal renal replacement therapy, patients may experience various complications during the follow-up. Therefore, they should be monitored regularly

scholarly journals Anemia Identified One Month after Renal Transplantation is Predictive of Anemia Identified After Twelve Months

2009 ◽  
Vol 9 (3) ◽  
pp. 221-224 ◽  
Author(s):  
Goran Imamović ◽  
Enver Zerem ◽  
Safet Omerović
Keyword(s):  
Renal Transplantation ◽  
Linear Regression ◽  
Serum Creatinine ◽  
Cohort Studies ◽  
Linear Regression Model ◽  
Multiple Linear Regression Model ◽  
Cross Sectional ◽  
Clinical Records ◽  
Modern Era

The aim of this study was to evalúate whether anemia identified earlier than 3 months postengraftment in modern era could be predictive of anemia at 12 months. Cross-sectional and cohort studies based on retrospective analysis of existing clinical records were performed. Data on recipient’s age at transplantation, follow-up serum creatinine (SCR) and hemoglobin (Hb) on day 7 (D7), at month 1 (M1) and at month 3 (M3) postengraftment were collected. Outcome was anemia identified at 12 months (M12) postengraftment. There were 75 patients on D7, 74 at M1 and 61 at M3. Multiple linear regression model that included recipient’s age at transplantation, Hb and creatinine on D7 and tested the risk for anemia at M12 retained only the age in the model, with the coefficient of 0,84 (P=0,001). The same model at M1 retained Hb and age, with the coefficients of 0,26 (P=0,03) and 0,81 (P=0,0002), respectively and at M3 it retained Hb and age, with the coefficients of 0,41 (P=0,004) and 0,70 (P=0,003), respectively. Anemia identified at M1 after renal transplantation is predictive of anemia at M12.

Sign in / Sign up

Export Citation Format

Share Document